Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab.

Neda RazazFredrik PiehlThomas FrisellAnnette M Langer-GouldKyla A McKayKatharina Fink

Published in: Neurology(R) neuroimmunology & neuroinflammation (2020)

This study provides Class IV evidence that in patients with MS who were on treatment before pregnancy, RTX reduces clinical disease activity compared with NTZ in the postpartum period.

Keyphrases

disease activity
rheumatoid arthritis
systemic lupus erythematosus
multiple sclerosis
rheumatoid arthritis patients
ankylosing spondylitis
mass spectrometry
juvenile idiopathic arthritis
preterm birth
ms ms
pregnancy outcomes
diffuse large b cell lymphoma
pregnant women
combination therapy